Skip to content
value.today

Alkermes plc.: financial analysis

Ratios worked out from 10 fiscal years of Alkermes plc.'s statements, compared with 665 companies in Biotechnology.

Operating margin, 2025
17.2%
Biotechnology: -60.5%
Return on equity, 2025
14.7%
Biotechnology: -61.0%
Revenue growth, 3 years a year, 2025
9.9%
Biotechnology: 12.9%
Debt to equity, 2025
0.00×
Biotechnology: 0.26×

Alkermes plc. scorecard#

Passes 15 of the 24 checks that could be worked out: strongest in financial health (5 of 5), weakest in growth (2 of 6). Fiscal year 2025; market cap of Oct 14, 2026.

  • Valuation3 of 6
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.7×Price to book 3.7× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median3.8×Price to sales 3.8× against Biotechnology's median of 8.7×.
    • ✓Free cash flow yield above 5%7.2%Free cash flow is 7.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • ✓The price assumes slower growth than the last three years'4.3%The price assumes 4.3% a year for ten years; revenue grew 9.9% a year over the last three.
  • Growth2 of 6
    • ✗Revenue grew in the newest year-5.2%Revenue down 5.2% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years9.9%9.9% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median9.9%9.9% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year1.43 vs 2.17Diluted EPS 1.43 in fiscal 2025 against 2.17 the year before (report's currency).
    • ✓Net income higher than five years earlier$242 M$242 M in fiscal 2025 against -$111 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability4 of 6
    • ✓Profitable in the newest year$242 MNet income $242 M in fiscal 2025.
    • ✗Profitable in each of the last five years3 of 5Profitable in 3 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median17.2%17.2% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%14.7%14.7% in fiscal 2025.
    • ✓Return on invested capital above 10%14.7%14.7% in fiscal 2025.
    • ✓Operating margin wider than three years earlier17.2%17.2% in fiscal 2025 against -0.5% in 2022.
  • Financial health5 of 5
    • ✓Short-term assets cover short-term liabilities3.5×Current ratio 3.55 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $389 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone7.18Z-score 7.18 (safe zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-0.3%Diluted shares down 0.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • More cash than debt: net cash of $389 million.

Worth a look

  • Revenue fell 5.2% against the year before.

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

5of 8(1 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseyes
  • No new shares issuedno
  • Gross margin roseyes
  • Asset turnover roseno

Altman Z-score

A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.

7.18Safe zone(above 2.99, where the formula's author found few failures)
The five parts of the Altman Z-score
PartRatioWeightPoints
Working capital to assets0.56× 1.20.67
Retained earnings to assets-0.29× 1.4-0.41
Operating income to assets0.10× 3.30.34
Market value to liabilities10.00× 0.66.00
Revenue to assets0.59× 10.59

Where the return on equity comes from

The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.

Net margin16.4%Asset turnover0.65×Assets to equity1.38×Return on equity14.7%

Profitability#

Alkermes plc.: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Gross margin86.7%84.3%84.8%80.4%83.2%74.8%63%
Operating margin17.2%27.0%24.9%-0.6%8.3%-60.5%85%
Net margin16.4%23.6%21.4%-14.2%-4.1%-68.9%83%
Return on equity14.7%27.5%31.7%-14.7%-4.4%-61.0%92%
Return on assets10.6%17.5%17.4%-7.9%-2.4%-44.4%93%
Return on invested capital14.7%———8.0%17.3%40%

Growth#

Alkermes plc.: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth-5.3%-6.4%49.6%-5.3%13.0%15.8%28%
Revenue growth, 3 years a year9.9%9.9%17.0%-1.7%2.4%12.9%46%
Revenue growth, 5 years a year7.3%5.9%8.7%4.2%9.5%15.4%36%
Net income growth-34.2%3.2%———10.1%9%
Earnings per share growth-34.1%3.3%———7.6%18%

Financial strength#

Alkermes plc.: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Debt to equity0.00×—0.24×0.28×0.26×0.26×82%
Net debt$-389 M—$-170 M$-2 M$-45 M$-16 M94%
Net debt to EBITDA-1.38×—-0.35×-0.03×-0.25×0.05×89%
Interest cover——17.98×-0.47×8.71×-22.77×—
Current ratio3.55×3.04×2.86×2.27×2.25×4.39×41%
Equity share of assets73.2%71.3%56.3%53.1%55.0%64.7%60%

Cash#

Alkermes plc.: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$480 M$406 M$353 M$-17 M$74 M$-40 M97%
Free cash flow margin32.5%26.0%21.2%-1.6%6.3%-61.5%94%
Cash conversion215.5%119.6%112.8%——72.6%86%
Capital spending share of revenue2.7%2.2%2.9%3.4%2.4%1.7%—

Shareholder returns#

Alkermes plc.: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Change in share count-0.3%-0.3%3.7%-0.6%3.8%17.3%94%

Efficiency#

Alkermes plc.: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover0.65×0.74×0.81×0.56×0.59×0.26×81%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Return on invested capital
Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Net debt to EBITDA
Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Alkermes plc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Alkermes plc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Alkermes plc.